Blauvelt, Andrew, Phoebe Rich, Howard Sofen, Jo Lambert, Joe Merola, Mark Lebwohl, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, and Alexa Kimball. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 6, no. 4 (July 7, 2022): s41. Accessed August 10, 2022. https://jofskin.org/index.php/skin/article/view/1666.